ADARx Pharmaceuticals, Inc. ADRX
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.13M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.13M | -- | -- | -- | -- |
| Cost of Revenue | 89.87M | -- | -- | -- | -- |
| Gross Profit | -83.74M | -- | -- | -- | -- |
| SG&A Expenses | 22.56M | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.43M | -- | -- | -- | -- |
| Operating Income | -106.30M | -- | -- | -- | -- |
| Income Before Tax | -87.87M | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.87 | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.87M | -- | -- | -- | -- |
| EBIT | -106.30M | -- | -- | -- | -- |
| EBITDA | -105.12M | -- | -- | -- | -- |
| EPS Basic | -7.74 | -- | -- | -- | -- |
| Normalized Basic EPS | -4.84 | -- | -- | -- | -- |
| EPS Diluted | -7.74 | -- | -- | -- | -- |
| Normalized Diluted EPS | -4.84 | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 45.41M | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 45.41M | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |